MedTrace Logo

Evaluation of NEUROCAP® In the Treatment of Symptomatic Neuroma

NCT02993276 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 73

Last updated 2020-09-10

No results posted yet for this study

Summary

PROSPECTIVE COHORT EVALUATION OF NEUROCAP® In the Treatment of symptomatic Neuroma (PROTECT Neuro)

This post-market surveillance study is conducted to provide post market surveillance information regarding long-term performance and ease of use of the Polyganics nerve capping device (NEUROCAP®) for reduction of the development of peripheral symptomatic end-neuroma.

Conditions

  • Neuroma

Interventions

DEVICE

Neurocap®

NEUROCAP®, a bioresorbable nerve capping device based upon the NEUROLAC® nerve guide, is indicated to protect a peripheral nerve end and to separate the nerve from surrounding environment to reduce the development of a symptomatic neuroma.

Sponsors & Collaborators

  • Polyganics BV

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-17
Primary Completion
2018-07-06
Completion
2020-08-30

Countries

  • United States
  • France
  • Germany
  • Italy
  • Spain
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02993276 on ClinicalTrials.gov